Milwaukee, WINCT05848713Now EnrollingIRB Ready

Pneumonia Clinical Trial in Milwaukee, WI

Access cutting-edge pneumonia treatment through this phase 3 clinical trial at a research site in Milwaukee. Study-provided care at no cost to qualified participants.

Sponsored by University of Manitoba

Quick Self-Assessment

See if you qualify for this Milwaukee location

Preparing your pre-screening questions…

Expert Care in Milwaukee

Access pneumonia specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related pneumonia treatment provided free

Apply for This Milwaukee Location

Check if you qualify for this pneumonia clinical trial in Milwaukee, WI

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Milwaukee

    Convenient for WI residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Milwaukee site if eligible
  4. 4Begin participation

About This Pneumonia Study in Milwaukee

This is an international, open-label, stratified randomized controlled trial with Bayesian adaptive stopping rules to compare the effects of therapeutic-dose heparin vs. usual care pharmacological thromboprophylaxis on outcomes in patients admitted to hospital with community acquired pneumonia (CAP).

Sponsor: University of Manitoba

Who Can Participate

Inclusion Criteria

Patients ≥18 years of age
Admitted to hospital for a suspected or confirmed diagnosis of CAP defined by:
Radiographic evidence of new or worsening infiltrate
One or more of the following signs and/or symptoms of lower respiratory tract infection i. New or increased cough or sputum production ii. Fever of \> 37.8C or temperature \< 36C iii. WBC \> 11 x 109/L or \< 4 x 109/L c. The primary diagnosis is believed to be CAP as per the attending physician
Requires supplemental oxygen to treat hypoxemia (or requires an increased level of supplemental oxygen if on chronic oxygen therapy)
Hospital admission anticipated to last ≥72 hours from randomization

Exclusion Criteria

Suspected or confirmed active COVID-19 infection
Hospital admission for \>72 hours prior to randomization
Patients receiving non-invasive or invasive ventilation, vasopressors, or extracorporeal life support (ECLS) within an ICU at the time of enrollment
Requirement for chronic mechanical ventilation via tracheostomy prior to hospitalization
Patients for whom the intent is to not use pharmacologic thromboprophylaxis
Patients with an independent indication for therapeutic-dose anticoagulation
Patients with a contraindication to therapeutic-dose anticoagulation, including:
Non-traumatic bleeding that requires medical evaluation or hospitalization within 30 days prior to CAP hospital admission
History of an inherited or acquired bleeding disorder
Cerebral aneurysm or mass lesions of the central nervous system
Ischemic stroke within 3 months of hospital admission
Gastrointestinal bleeding within 3 months of hospital admission
Platelet count \<50 x109/L OR INR \>2.0 OR hemoglobin \<80 g/L at the time of screening
Other physician-perceived contraindications to therapeutic anticoagulation
History of heparin induced thrombocytopenia (HIT) or other heparin allergy
Current or recent (within 7 days of screening) use of dual anti-platelet inhibitors (For example; Aspirin + one of the following; clopidogrel, ticagrelor, prasugrel)
Patients in whom imminent death is anticipated
Anticipated transfer to another hospital that is not a study site within 72 hours of randomization
Enrollment in other interventional trials related to anticoagulation or antiplatelet therapy during current hospitalization

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Milwaukee?

Yes, this clinical trial (NCT05848713) has an active research site in Milwaukee, WI that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Pneumonia Treatment Options in Milwaukee, WI

If you're searching for pneumonia treatment options in Milwaukee, WI, this clinical trial (NCT05848713) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Milwaukee research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced pneumonia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all pneumonia clinical trials near you to find additional studies recruiting in your area.

More Pneumonia Trials in Milwaukee, WI

See all pneumonia clinical trials recruiting in Milwaukee — not just this study.

Browse Pneumonia Trials in Milwaukee →

Browse More Trials by Condition

Pneumonia TrialsPrurigo Nodularis TrialsAll Conditions →

Ready to Join in Milwaukee?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Milwaukee, WI